Alirocumab reduced the risk of recurrent ischemic cardiovascular events compared to placebo in patients on high-intensity statin therapy post-acute coronary syndrome.
Does alirocumab reduce recurrent ischemic cardiovascular events in patients with previous acute coronary syndrome receiving high-intensity statin therapy?
Alirocumab reduces the risk of recurrent ischemic cardiovascular events in patients with a history of acute coronary syndrome on background high-intensity statin therapy.
Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY OUTCOMES ClinicalTrials.gov number, NCT01663402 .).
Long-term legacy effects and cost-effectiveness still discussed in context of 2026 aggressive lipid lowering trials and new guidelines.
Schwartz et al. (2018) studied this question. Alirocumab reduced the risk of recurrent ischemic cardiovascular events compared to placebo in patients on high-intensity statin therapy post-acute coronary syndrome.